Auburn Fever (African Trypanosomiasis)

What is Auburn fever (African trypanosomiasis)?

Auburn fever, more commonly known as African trypanosomiasis or sleeping sickness, is a parasitic disease caused by infection with Trypanosoma species transmitted through the bite of infected tsetse flies (Glossina spp.). The disease is endemic to sub‑Saharan Africa, affecting rural communities where humans, livestock, and wildlife interact with the fly’s habitat. The term “auburn fever” historically referred to the reddish‑brown (auburn) discoloration of the skin that can appear during the early haemolymphatic stage, but the modern medical community uses “African trypanosomiasis” to describe both stages of the infection.

The illness progresses in two stages:

• Stage 1 – haemolymphatic (early) stage: Parasites multiply in the blood and lymph, causing fever, headaches, joint pain, and the characteristic skin changes.
• Stage 2 – meningo‑encephalitic (late) stage: Parasites cross the blood‑brain barrier, leading to neurological signs such as sleep disturbances, confusion, and severe motor impairment.

If untreated, the disease is almost always fatal. Early recognition and treatment dramatically improve outcomes, which is why awareness of the signs and risk factors is essential for travelers, expatriates, and residents of endemic regions.

Common Causes

Although the primary cause is infection with Trypanosoma brucei subspecies, several related conditions or situations can mimic or predispose to Auburn fever:

• Trypanosoma brucei rhodesiense infection – East African form, typically acute with rapid progression.
• Trypanosoma brucei gambiense infection – West/Central African form, chronic and slower‑onset.
• Other trypanosome species – e.g., T. congolense or T. vivax (mostly animal disease but rare zoonotic cases).
• Co‑infection with malaria – overlapping febrile illnesses can mask trypanosomiasis.
• Secondary bacterial infections – skin lesions may become infected with Staphylococcus or Streptococcus.
• Auto‑immune disorders – Lupus or rheumatoid arthritis can cause fever and joint pain that resemble early stage disease.
• Other vector‑borne fevers – such as rift valley fever or dengue, which share geographic distribution.
• Chronic viral infections – hepatitis B/C or HIV can alter immune response, worsening trypanosome infection.
• Exposure to contaminated water sources – may predispose to secondary infections that complicate the clinical picture.
• Travel to endemic regions without prophylaxis – the most direct risk factor for acquiring the disease.

Associated Symptoms

Symptoms differ between the early and late stages but can overlap. Common manifestations include:

• Sudden onset fever (often intermittent)
• Headache and severe malaise
• Joint and muscle aches (arthralgia, myalgia)
• Auburn‑colored skin rash or macular discoloration, especially on the trunk
• Swollen lymph nodes (especially cervical)
• Difficulty sleeping – patients may appear “asleep” during the day and restless at night (“sleeping sickness”)
• Neurological signs in Stage 2:
  • Confusion, irritability, or personality changes
  • Speech disturbances, tremors, or ataxia
  • Seizures (rare but reported)
  • Loss of coordination and gait abnormalities
• Gastrointestinal symptoms: nausea, vomiting, loss of appetite
• Weight loss and generalized cachexia in chronic infection

When to See a Doctor

Because African trypanosomiasis can progress rapidly, seek medical attention promptly if you experience any of the following:

• Fever lasting more than 48 hours after returning from or living in a tsetse‑fly endemic area.
• Unexplained skin rash with a reddish‑brown hue, especially combined with fever.
• Severe headache, neck stiffness, or neurological changes (confusion, slurred speech, difficulty walking).
• Persistent joint or muscle pain that does not improve with over‑the‑counter analgesics.
• Signs of dehydration, persistent vomiting, or inability to keep fluids down.
• Any *sudden* change in sleep patterns (extreme daytime sleepiness or nighttime insomnia) after possible exposure.

Early evaluation may prevent progression to the fatal second stage. If you are a traveler, inform the clinician about all recent trips, even those that seem brief.

Diagnosis

Diagnosing African trypanosomiasis involves a combination of clinical suspicion, laboratory testing, and imaging when neurological involvement is suspected.

1. Clinical assessment

A thorough history (travel, occupational exposure, wildlife contact) and physical examination (skin findings, lymphadenopathy, neurologic exam) guide further testing.

2. Laboratory tests

• Microscopic examination: Wet blood smears or lymph node aspirates stained with Giemsa or acridine orange can reveal motile trypomastigotes.
• Concentration techniques: The micro‑haematocrit centrifugation technique (mHCT) or mini‑anion exchange centrifugation technique (mAECT) increase sensitivity.
• Polymerase chain reaction (PCR): Detects trypanosomal DNA and can differentiate between T. b. rhodesiense and T. b. gambiense (highly specific, used in reference labs).
• Serology: Card Agglutination Test for Trypanosomiasis (CATT) is widely used for screening in endemic areas; ELISA may be employed in research settings.
• Blood counts: May show anemia, leukopenia, or thrombocytopenia.
• CSF analysis (Stage 2): Lumbar puncture to assess white‑blood‑cell count, protein, and presence of parasites in cerebrospinal fluid.

3. Imaging (when needed)

• MRI or CT scan: May show nonspecific brain changes (e.g., diffuse atrophy, ventricular enlargement) but are primarily used to rule out other causes of encephalopathy.

4. Differential diagnosis

Conditions that can mimic the presentation include malaria, typhoid fever, viral hemorrhagic fevers, leptospirosis, and rheumatologic disorders. Laboratory confirmation is essential before initiating specific antiparasitic therapy.

Treatment Options

Treatment is stage‑specific and must be administered under the supervision of an infectious‑disease specialist or a clinician experienced with tropical diseases.

Early (Stage 1) Treatment

• Pentamidine isethionate (for T. b. gambiense): 4 mg/kg IV or IM daily for 7 days. Side effects include hypotension, renal toxicity, and nausea.
• Suramin (for T. b. rhodesiense): 20 mg/kg IV on day 1, then 20 mg/kg on day 3, 5, 7, 9, and 11. Requires careful monitoring for allergic reactions and renal dysfunction.

Late (Stage 2) Treatment

• Eflornithine (for T. b. gambiense): 100 mg/kg IV every 6 hours for 14 days. Considered less toxic than melarsoprol.
• Melarsoprol (for both subspecies when eflornithine unavailable): 2.2 mg/kg IV daily for 10 days. Highly neurotoxic; can cause reactive encephalopathy in up to 10 % of patients.
• Nifurtimox‑eflornithine combination therapy (NECT): Recommended by WHO for T. b. gambiense Stage 2; reduces treatment duration and toxicity.

Supportive and Home Care

• Maintain adequate hydration and nutrition; loss of appetite is common.
• Antipyretics (acetaminophen or ibuprofen) for fever and headache.
• Rest in a quiet, well‑ventilated environment; reduce sensory overstimulation during the neurological phase.
• Monitor blood pressure and renal function if on pentamidine or suramin.
• Family education on medication adherence – incomplete courses can lead to relapse.

Prevention Tips

Because there is no vaccine, prevention focuses on vector control and personal protective measures.

• Avoid tsetse‑fly habitats during peak activity (warm, humid periods; riverine and forest edges).
• Wear protective clothing: Long‑sleeved shirts, long trousers, and hats; tuck clothing into socks.
• Use insect repellents containing DEET (20‑30 %) or picaridin on exposed skin.
• Apply insecticide‑treated clothing (permethrin‑treated) for added protection.
• Stay in screened or air‑conditioned accommodations where possible.
• Use traps and odor‑baited targets in community settings to reduce fly populations (effective in some endemic villages).
• Participate in mass screening programs in endemic countries; early detection reduces transmission.
• Educate travelers about the signs of early disease and the importance of seeking care promptly after returning.
• For livestock owners, treat animals with trypanocidal drugs (e.g., diminazene) as part of a One‑Health approach.

Emergency Warning Signs

Immediate medical attention is required if any of the following occur:

• Severe or uncontrolled fever (> 39.5 °C) lasting > 48 hours.
• Sudden neurological deterioration – confusion, seizures, loss of consciousness, or severe headache with neck stiffness.
• Rapidly worsening sleep‑wake cycle causing dangerous daytime somnolence (risk of accidents).
• Signs of severe dehydration (dry mouth, scant urine, dizziness) despite fluid intake.
• Allergic reaction to medication (rash, swelling of face or throat, difficulty breathing) during treatment.
• Persistent vomiting that prevents oral medication or fluid intake.

Call emergency services or go to the nearest hospital if you or someone you care for exhibits any of these symptoms.

Key Take‑aways

• Auburn fever (African trypanosomiasis) is a life‑threatening parasitic disease transmitted by tsetse flies.
• Early stage presents with fever, headache, joint pain, and a characteristic auburn‑colored rash; late stage involves severe neurologic signs.
• Diagnosis requires microscopic or molecular detection of parasites and, for Stage 2, CSF analysis.
• Treatment differs by stage and subspecies; prompt therapy with pentamidine, suramin, eflornithine, or NECT can cure the disease.
• Prevention relies on vector avoidance, repellents, protective clothing, and community‑level control measures.
• Any rapid neurological change, high fever, or treatment reaction is an emergency—seek help immediately.

For the most up‑to‑date guidelines, consult resources such as the World Health Organization (WHO) African Trypanosomiasis Control Programme, the Centers for Disease Control and Prevention (CDC), and trusted medical centers like the Mayo Clinic and Cleveland Clinic.

---

References:

• World Health Organization. Control and surveillance of human African trypanosomiasis. 2023. WHO Publication.
• CDC. “African Trypanosomiasis (Sleeping Sickness).” 2024. CDC.
• Mayo Clinic. “Trypanosomiasis.” 2024. Mayo Clinic.
• Cleveland Clinic. “African Sleeping Sickness (Human African Trypanosomiasis).” 2023. Cleveland Clinic.
• Harrison’s Principles of Internal Medicine, 21st ed., 2024.